MEDIGENE

Welcome to the Brand page for “MEDIGENE”, which is offered here for Pharmaceutical and veterinary preparations namely, cellular preparations, t-cell preparations and dc (dendritic cell) preparations for the treatment of cancer and use in immunotherapy; medical compositions for the treatment of hematological and solid tumors, tumor precursors; test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of antibodies, test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of soluble t-cell receptors, test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting primarily of genetically modified cells and test kits for diagnostic preparations for medical purposes for determining the type and existence of a tumor in a patient consisting of a composition of antibodies, soluble t-cell receptors and genetically modified cells; diagnostic and therapeutic preparations for medical purposes being mixtures of therapeutically active cells in a suitable medium, in particular produced using molecular biological, biotechnological and genetic methods;color is not claimed as a feature of the mark.;medical and veterinary medical services, in particular extracting of blood and/or tissue samples and analysis and evaluation relating thereto for medical purposes;services in molecular biology, research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological and genetic methods, and in the field of screening for compounds with pharmaceutical properties; development of test methods and test kits in the field of hematological and solid tumor immunology; biological cell analyses; development of individualized medicine, development of treatment plans and therapy adapted for individual patients; all the foregoing being for scientific and therapeutic purposes; development of adoptive t cell therapy; development of dc vaccines; development of cellular tumour therapy; development of tumour markers; development of diagnostic and therapeutic antibodies; cell analyses; development of individualised medicine, development of treatment plans and therapy adapted for individual patients;.

Its status is currently believed to be active. Its class is unavailable. “MEDIGENE” is believed to be currently owned by “Medigene Immunotherapies GmbH”.